Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

Journal of General Virology

Volumn 80, Issue 3, 1999, Pages 601-606

  Ling, R ^a   Harrison, T J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; VIRUS DNA;

ARTICLE; DNA REPLICATION; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS REPLICATION;

EID: 0033031769     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-80-3-601     Document Type: Article

References (30)

1. Allen, M. I., Deslauriers, M., Andrews, C. W., Tipples, G. A., Walters, K. A., Tyrrell, D. L., Brown, N. & Condreay, L. D. (1998). Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27, 1670-1677.
2. Bain, V. G., Kneteman, N. M., Ma, M. M., Gutfreund, K., Shapiro, J. A., Fischer, K., Tipples, G., Lee, H., Jewell, L. D. & Tyrrell, D. L. (1996). Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62, 1456-1462.
3. Bartholomew, M. M., Jansen, R. W., Jeffers, L. J., Reddy, K. R., Johnson, L. C., Bunzendahl, H., Condreay, L. D., Tzakis, A. G., Schiff, E. R. & Brown, N. A. (1997). Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [see comments]. Lancet 349, 20-22.
4. Ben-Ari, Z., Shmueli, D., Mor, E., Shaharabani, E., Bar-Nathan, N., Shapira, Z. & Tur-Kaspa, R. (1997a). Beneficial effect of lamivudine pre- and post-liver transplantation for hepatitis B infection. Transplantation Proceedings 29, 2687-2688.
5. Ben-Ari, Z., Shmueli, D., Mor, E., Shapira, Z. & Tur-Kaspa, R. (1997b). Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 63, 393-396.
6. Buti, M., Jardi, R., Cotrina, M., Rodriguez-Frias, F., Esteban, R. & Guardia, J. (1998). Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. Journal of Hepatology 28, 510-513.
7. Chayama, K., Suzuki, Y., Kobayashi, M., Tsubota, A., Hashimoto, M., Miyano, Y., Koike, H., Koida, I., Arase, Y., Saitoh, S., Murashima, N., Ikeda, K. & Kumada, H. (1998). Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27, 1711-1716.
8. Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C. & Rubin, M. (1995). A preliminary trial of lamivudine for chronic hepatitis B infection [see comments]. New England Journal of Medicine 333, 1657-1661.
9. Fu, L. & Cheng, Y. C. (1998). Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochemical Pharmacology 55, 1567-1572.
10. Grellier, L., Mutimer, D., Ahmed, M., Brown, D., Burroughs, A. K., Rolles, K., McMaster, P., Beranek, P., Kennedy, F., Kibbler, H., McPhillips, P., Elias, E. & Dusheiko, G. (1996). Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348, 1212-1215.
11. Honkoop, P., Niesters, H. G., de Man, R. A., Osterhaus, A. D. & Schalm, S. W. (1997). Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. Journal of Hepatology 26, 1393-1395.
12. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. & Steitz, T. A. (1992). Crystal structure at 3·5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790.
13. Ladner, S. K., Miller, T. J. & King, R. W. (1998). The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrobial Agents and Chemotherapy 42, 2128-2131.
14. Lai, C. L., Ching, C. K., Tung, A. K., Li, E., Young, J., Hill, A., Wong, B. C., Dent, J. & Wu, P. C. (1997). Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25, 241-244.
15. Larder, B. A., Kemp, S. D. & Purifoy, D. J. (1989). Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proceedings of the National Academy of Sciences, USA 86, 4803-4807.
16. Ling, R. & Harrison, T. J. (1997). Production of hepatitis B virus covalently closed circular DNA in transfected cells is independent of surface antigen synthesis. Journal of General Virology 78, 1463-1467.
17. Ling, R., Mutimer, D., Ahmed, M., Boxall, E. H., Elias, E., Dusheiko, G. M. & Harrison, T. J. (1996). Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24, 711-713.
18. Markowitz, J. S., Martin, P., Conrad, A. J., Markmann, J. F., Seu, P., Yersiz, H., Goss, J. A., Schmidt, P., Pakrasi, A., Artinian, L., Murray, N. G., Imagawa, D. K., Holt, C., Goldstein, L. I., Stribling, R. & Busuttil, R. W. (1998). Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28, 585-589.
19. Melegari, M., Scaglioni, P. P. & Wands, J. R. (1998). Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27, 628-633.
20. Muller, R., Samuel, D., Fassati, L. R., Benhamou, J. P., Bismuth, H. & Alexander, G. J. (1994). 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. Journal of Hepatology 21, 1140-1143.
21. Nevens, F., Main, J., Honkoop, P., Tyrrell, D. L., Barber, J., Sullivan, M. T., Fevery, J., De Man, R. A. & Thomas, H. C. (1997). Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113, 1258-1263.
22. Niesters, H. G., Honkoop, P., Haagsma, E. B., de Man, R. A., Schalm, S. W. & Osterhaus, A. D. (1998). Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. Journal of Infectious Diseases 177, 1382-1385.
23. Ono, Y., Onda, H., Sasada, R., Igarashi, K., Sugino, Y. & Nishioka, K. (1983). The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Research 11, 1747-1757.
24. Schalm, S. W., de Man, R. A., Heijtink, R. A. & Niesters, H. G. (1995). New nucleoside analogues for chronic hepatitis B. Journal of Hepatology 22, 52-56.
25. Tipples, G. A., Ma, M. M., Fischer, K. P., Bain, V. G., Kneteman, N. M. & Tyrrell, D. L. (1996). Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24, 714-717.
26. Tisdale, M., Kemp, S. D., Parry, N. R. & Larder, B. A. (1993). Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 90, 5653-5656.
27. Toh, H., Hayashida, H. & Miyata, T. (1983). Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 305, 827-829.
28. Vaudin, M., Wolstenholme, A. J., Tsiquaye, K. N., Zuckerman, A. J. & Harrison, T. J. (1988). The complete nucleotide sequence of the genome of a hepatitis B virus isolated from a naturally infected chimpanzee. Journal of General Virology 69, 1383-1389.
29. Wainberg, M. A., Salomon, H., Gu, Z., Montaner, J. S., Cooley, T. P., McCaffrey, R., Ruedy, J., Hirst, H. M., Cammack, N., Cameron, J. and others (1995). Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9, 351-357.
30. Wainberg, M. A., Hsu, M., Gu, Z., Borkow, G. & Parniak, M. A. (1996). Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. AIDS 10, S3-10.